| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871241 | ALIMERA SCIENCES INC | Injectable sustained release delivery devices |
Aug, 2027
(3 years from now) | |
Iluvien is owned by Alimera Sciences Inc.
Iluvien contains Fluocinolone Acetonide.
Iluvien has a total of 1 drug patent out of which 0 drug patents have expired.
Iluvien was authorised for market use on 26 September, 2014.
Iluvien is available in implant;intravitreal dosage forms.
The generics of Iluvien are possible to be released after 12 August, 2027.
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: NA
Dosage: IMPLANT;INTRAVITREAL
More Information on Dosage
ILUVIEN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic